Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in Business, Pipeline

How former Acorda CEO Ron Cohen landed at a Parkinson’s cell therapy startup

 March 24, 2026

BioPharma Dive

Cohen says he looked at around two dozen companies since Acorda wound down.

PipelineNeuroscience Read full story

Post navigation

Pfizer, Valneva to seek approval of Lyme disease vaccine despite mixed study results →
← NOW AVAILABLE: The 2026 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com